Marché mondial du traitement de la maladie de Whitmore – Tendances et prévisions de l'industrie jusqu'en 2029

Analyse et perspectives du marché : marché mondial du traitement de la maladie de Whitmore

Le marché du traitement de la maladie de Whitmore devrait connaître une croissance exponentielle au cours de la période de prévision 2022-2029. Data Bridge Market Research analyse le marché pour s'attendre à une croissance à un TCAC de 4,20 % au cours de la période de prévision mentionnée ci-dessus.

La maladie de Whitmore, également connue sous le nom de mélioïdose, est une infection bactérienne qui peut toucher les humains comme les animaux. B. pseudomallei est l'organisme responsable de cette infection. Ces bactéries ont la capacité de polluer l'eau et le sol. Les personnes peuvent contracter l'infection en inhalant de l'eau ou de la poussière contaminée, en buvant ou en mangeant des aliments qui ont été en contact avec ces sources, ou en entrant en contact avec de la saleté ou de l'eau contaminée sur leur peau. La maladie de Whitmore touche le plus souvent les poumons, où l'infection peut entraîner un abcès rempli de pus. Les germes peuvent également passer de la peau au cerveau, au cœur, aux reins, aux yeux, au foie et aux articulations via la circulation sanguine.

L'augmentation de la prévalence de la maladie de Whitmore et l'augmentation des dépenses de santé sont les principaux facteurs qui influencent le taux de croissance du marché. En outre, les progrès de la technologie médicale, l'augmentation du financement gouvernemental et les initiatives croissantes des organisations publiques et privées pour faire connaître la maladie et ses options préventives sont les facteurs qui vont développer le marché du traitement de la maladie de Whitmore. D'autres facteurs, notamment la forte consommation d'alcool et l'augmentation des cas de diabète, de cancer et de maladies pulmonaires chroniques, auront un impact positif sur le taux de croissance du marché.

De plus, l’augmentation des activités de recherche et développement et l’émergence de nouveaux marchés offriront des opportunités bénéfiques pour le marché du traitement de la maladie de Whitmore au cours de la période de prévision 2022-2029.

However, high cost of the treatment and complications associated with the disease are the factors that will hinder the market growth. Lack of awareness will further challenge the Whitmore’s disease treatment market in the forecast period mentioned above.

This Whitmore’s disease treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Whitmore’s disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Whitmore’s Disease Treatment Market Scope and Market Size

The Whitmore’s disease treatment market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of type, the Whitmore’s disease treatment market is segmented into pulmonary infection, localized infection, bloodstream infection and disseminated infection.
• On the basis of treatment, the Whitmore’s disease treatment market is segmented into antimicrobial therapy and others. Antimicrobial therapy is further sub-segmented into intravenous antimicrobial therapy and oral antimicrobial therapy.  
• On the basis of diagnosis, the Whitmore’s disease treatment market is segmented into blood test, urine sample, throat swab and skin lesion test.
• On the basis of symptoms, the Whitmore’s disease treatment market is segmented into fever, cough, respiratory distress, chest pain, abscess formation and others.
• On the basis of dosage, the Whitmore’s disease treatment market is segmented into tablet, injection and others.
• On the basis of route of administration, the Whitmore’s disease treatment market is segmented into oral, intravenous and others.
• On the basis of end-users, the Whitmore’s disease treatment market is segmented into clinic, hospital and others.

The Whitmore’s disease treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Whitmore’s Disease Treatment Market Country Level Analysis

Whitmore’s disease treatment market is analyzed and market size information is provided by the country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Whitmore’s disease treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the Whitmore’s disease treatment market due to presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Whitmore’s disease treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Whitmore’s Disease Treatment Market Share Analysis

Le paysage concurrentiel du marché du traitement de la maladie de Whitmore fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée à l'étude de marché sur le traitement de la maladie de Whitmore.

Français Certains des principaux acteurs opérant sur le marché du traitement de la maladie de Whitmore sont Allergan, Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc, Spero Therapeutics, Abbott, F. Hoffmann-La Roche Ltd., Mylan NV, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, SHIONOGI & Co., Ltd., AbbVie Inc., Eli Lilly and Company, Cumberland Pharmaceuticals Inc., Johnson & Johnson Private Limited et Bristol-Myers Squibb Company, entre autres.

SKU-67353